Medical Applications of Siderophores

Basavraj Nagoba; Deepak Vedpathak

doi:10.29333/ejgm/82743

Full Text (PDF)

Basavraj Nagoba ¹ ^* , Deepak Vedpathak ²

More Detail

¹ Maharashtra Institute of Medical Science and Research Medical College, Latur, India² Rajarshi Shahu College, Latur, India^* Corresponding Author

Abstract

The literature survey presented in this review shows that the knowledge regarding the structure of various siderophores and the presence of microbial membrane receptors that operates in iron uptake from these iron – siderophore complexes have opened newer avenues for research. Siderophores and their substituted derivatives have a large number of applications in medical sciences. The most important application is selective drug delivery, a Trojan horse strategy, to defeat drug resistant bacteria. The Trojan horse strategy is most promising way to specifically attack multiple antibiotic resistant strains of bacteria associated with life threatening infections. Other major clinical applications include treatment of diseases like haemochromatosis, thalassemia, dialysis encephalopathy, removal of transuranic elements such as aluminium and vanadium and anti-malarial activity.

Keywords

siderophores
trojan horse strategy
medical applications

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Review Article

EUR J GEN MED, 2011, Volume 8, Issue 3, 229-235

https://doi.org/10.29333/ejgm/82743

Publication date: 11 Jul 2011

Article Views: 3158

Article Downloads: 2018

Open Access References How to cite this article

References

Chincholkar SB, Chaudhari BL, Talegaonkar SK, Kothari RM. Microbial iron chelators: A sustainable tool for the biocontrol of plant diseases. In: Upadhaya RK, Mukerji KG, and Chamola BP (eds.), Biocontrol potential and its exploitation in sustainable agriculture, New York; Kluwer Academic/Plenum Publishers, 2000; 49-70.
Barber SA. Iron; soil nutrient bioavailability- a mechanistic approach. John Wily and Sons Inc. 1995;330-7
Messenger A J M, and Ratledge C. Siderophores. In: Moo Young M. (eds.), Comprehensive biotechnology. Vol.3. Pergamon press, 1985; 275-295.
Carmen VS and Richard AF. Vibrio cholerae Expresses Iron-Regulated Outer Membrane Proteins In- Vivo. Infect Immun 1983;42(3);990-6.
Bulien JJ. The significance of iron in infection. Rev Infect Dis 1981;3:1127-38.
Finkelstein RA, Sciortino CV and McIntosh MA. Role of iron in microbe-host interactions. Rev Infect Dis 5(Suppl. 4):1983;759-77.
Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol Rev 1984;64:65–102.
Emery T. The storage and transport of iron, in: Metal ions in biological systems, Iron in model and natural compounds, H. Sigel (eds.), New York, Marcal Dekker Inc., 1977;7:77-125.
Neilands JB. Microbial iron compounds. Annu Rev Biochem 1981;50:715-31.
Neilands JB. Microbial envelope proteins related to iron. Annu Rev Microbiol 1982;36:285-309.
Lankford CE. Bacterial assimilation of iron. Crit Rev Microbiol 1973;2:273-331.
Neilands JB. Siderophores of bacteria and fungi. Microbiol Sci 1984;1:9-14.
Hofte M. Classes of microbial siderophores. In : Iron chelation in plants and soil microorganisms. Academic Press Inc. 1993;3-26.
Winkelman G. and Drechsel H. Microbial siderophores. In: products of secondary metabolism. Vol.7. Kleinkauf, H. and von Dohren, H.(eds.). Germany, Wiley –VCH. Weinheim, 1997;200-46.
Dertz EA, Jide Xu, Stintzi A, and Raymond K N. "Bacillibactin-Mediated Iron Transport in Bacillus Subtilis". J Am Chem Soc 2006;128(1):22–3.
Budzikiewicz H. Siderphores of the human pathogenic fluorescent pseudomonads. Curr Topics in Med Chem 2000; 11(1):1-6.
Gibson F and Margrath DI. The isolation and characterization of a hydroxamic acid (aerobactin) formed by Aerobacter aerogenes 62-I. Biochem Biophysics Acta 1969; 92:175-84.
Griffiths Gl, Sigel SP, Payne SM and Neilands JB. Vibriobactin, a siderophore from Vibrio cholerae. J Biol Chem 1984;259:383-5.
Snow GA. Mycobactins: iron-chelating growth factors from Mycobactaria. Bacteriol Rev 1970;34:99-125.
Perry RD, Balbo PB, Jones HA, Fetherston JD and Demoll E. Yersiniabactin from Yersinia pestis: biochemical characterization of the siderophore and its role in iron transport and regulation. Microbiology 1999;145:1171-90.
Courcol RJ, Trivier, D, Bissinger MC, Martin, GR and Brown, MRW. Siderophore production by Staphylococcus aureus and identification of iron-regulated proteins. Infect Immun 1997;65:1944–8.
Dale SE, Doherty-Kirby A, Lajoie G and Heinrichs DE. Role of siderophore biosynthesis in virulence of Staphylococcus aureus: identification and characterization of genes involved in production of a siderophore. Infect Immun 2004;72:29–37.
Ballouche M, Cornelis P and Baysse C. Iron Metabolism: A Promising Target for Antibacterial Strategies. Recent Pat Antiinfect Drug Discov 2009;4:190-205.
Miethke M and Marahiel M A. Siderophore-Based Iron Acquisition and Pathogen Control. Microbiol Mol Biol Rev 2007;71(3):413–51.
Ding P, Schous C E, Miller M J. Design and synthesis of a novel protected mixed ligand siderophore. Tetrahedron Lett 2008;49:2306–10.
Budzikiewicz H. Siderophore-Antibiotic Conjugates Used as Trojan Horses Against Pseudomonas aeruginosa 1. Curr Top Med Chem 2001;1:73-82.
Kinzel O, Tappe R, Gerus I.; Budzikiewicz H. The synthesis and antibacterial activity of two pyoverdin ampicillin conjugates, entering Pseudomonas aeruginosa via the pyoverdin-mediated iron uptake pathway. J Antibiotics. 1998;51:499-507.
Diarra MS, Lavoie MC, Jacques M, Darwish I, Dolence EK, Ghosh AJA, Miller MJ and Malouin F. Species selectivity of new siderophore – drug conjugates that use specific iron uptake for entry into bacteria. Antimicrob Agents Chemother 1996;40:2610-7.
Heevwer Budzikiewicz. Siderophore – Antibiotic conjugates as Trojan horses against Pseudomonas aeruginosa. Curr Top Biochem 2001;1:73-82.
Reedy J. Trojan horse strategy defeats drug resistant bacteria (online). 2007 June 9; Available from: File://D:\ siderophore\Trojan horse strategy defeats drug-resistant bacteria.htm
Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn F, Rosenthal A and Nathan DG. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977; 297: 418 – 423.
Robotham JL and Lietman PS. Acute iron poisoning – a review. Am J Dis Child 1980; 134: 875 – 897.
Summers MR, Jacobs A, Tudway D, Perera P and Rickets C. Studies in desfferoxamine and ferrioxamine metabolism in normal and iron loaded subjects. Br J Haematol 1979; 42: 547– 555.
Cao A, Gabutti V, Masera G, Modell B, Sarchia G and Vullo C. Management protocol for the treatment of thalessima patients. Newyork Cooly’s Anaemia Foundation.
Möllmann U, Heinisch L, Bauernfeind A, Köhler T, AnkelFuchs D. Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals 2009;22(4):615- 24.
Loyevsky M, John C, Dickens B, Hu V, Miller JH and Gordeuk VR. Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators. Mol Biochem Parasitol 1999;101:43- 59
Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A and Cabantchik ZI. The antimalareial action of desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J Clin Investig 1993; 91:218–24.
Gysin Jurg, Crenn, Yvwa, Preira da silva, Luiz, Breton, Catherine. Siderophores as anti parasitic agents. US patent 5, 1991:192, 807.
Ackrill P, Raiston AJ, Day and Hoodge KC. Successful removal of aluminum from patients with encephalopathy. Lancet 1980;2:692-3.
Arze RS, Parkinson IS, Cartilidge NEP, Britton P and Ward MK. Reversal of aluminum dialysis encephalopathy after desferrrioxamine treatment. Lancet 1981;2:1116.
Pogglitsch H, Petek W, Wawschinck O and Holzer. Treatment of early stages of dialysis encephalopathy by aluminium. Lancet 1981;2:1344-5.
Hansen TV, Aaxeth J and Alexander J. The effect of chelating agents on vanadium distribution in the rat body and on uptake by human erythrocytes. Arch Toxicology 1982; 50:195-202.
Johnson PA, Bebington GB, Landa, Andrew Sjakk, Markin, Stephan Anthony, Mckay Victroria Anne, 2003. Deodorant produts, US patent no. 6, 503,490.

How to cite this article

Vancouver

Nagoba B, Vedpathak D. Medical Applications of Siderophores. EUR J GEN MED. 2011;8(3):229-35. https://doi.org/10.29333/ejgm/82743

APA

Nagoba, B., & Vedpathak, D. (2011). Medical Applications of Siderophores. European Journal of General Medicine, 8(3), 229-235. https://doi.org/10.29333/ejgm/82743

AMA

Nagoba B, Vedpathak D. Medical Applications of Siderophores. EUR J GEN MED. 2011;8(3), 229-235. https://doi.org/10.29333/ejgm/82743

Chicago

Nagoba, Basavraj, and Deepak Vedpathak. "Medical Applications of Siderophores". European Journal of General Medicine 2011 8 no. 3 (2011): 229-235. https://doi.org/10.29333/ejgm/82743

Harvard

Nagoba, B., and Vedpathak, D. (2011). Medical Applications of Siderophores. European Journal of General Medicine, 8(3), pp. 229-235. https://doi.org/10.29333/ejgm/82743

MLA

Nagoba, Basavraj et al. "Medical Applications of Siderophores". European Journal of General Medicine, vol. 8, no. 3, 2011, pp. 229-235. https://doi.org/10.29333/ejgm/82743

Electronic Journal of General Medicine

Abstract

Keywords

License